Search Results - "Dorff, T.B"

Phase 1 Study of Increased Dose-per-Fraction Hypofractionated Radiation Therapy Following Radical Prostatectomy: Toxicity Assessment of 15 Fractions at 3.6 Gy per Fraction by Ballas, L.K, Aron, M, Chung, E, Shuryak, I, Dorff, T.B, Yang, D, Brenner, D.J, Groshen, S

Get full text

P0084 Eribulin in patients with advanced urothelial cancer and previously treated with platinum and anti-microtubule chemotherapy: A phase 2 California Cancer Consortium trial by Quinn, D.I, Twardowski, P.W, Ruel, N, Groshen, S.G, Dorff, T.B, Pal, S.K, Stadler, W.M, Gandara, D.R, Lara Jr, P.N, Newman, E.M

“…Background There is an unmet need for new agents in advanced urothelial cancer (UC). Antimicrotubule therapy (AMT; e.g. vincas and taxanes) has activity in UC…”
Get full text

7043 POSTER A Phase l/lI Trial of AN-152 in Castration- and Taxane-Resistant Prostate Cancer by Liu, S.V, Schally, A.V, Dorff, T.B, Groshen, S, Hawes, D, Quinn, D.I, Tai, Y.C, Block, N.L, Engel, J, Pinski, J

Get full text

PO-16 Hemostatic activation, fibrinolysis, and angiogenesis prior to radical retropubic prostatectomy by Tagawa, S.T, Dorff, T.B, Rochanda, L, Ye, W, Lieskovsky, G, Skinner, D.G, Quinn, D.I, Liebman, H.A

Get full text

Radium 223 Dichloride in Combination with Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients with Stage IV Oligometastatic Castration Sensitive Prostate Cancer: Clinical Trial in Progress by Dandapani, S.V., Dorff, T.B., Kortylewski, M., Frankel, P., Twardowski, P.

Get full text

Survey of Sexual Health Concerns among Patients with Treatment-Naïve Prostate Cancer by Tam, A., Huang, Z., Gonzalez, E. Lopez, Abuali, T., Correnti, N., DeWees, T.A., Maroongroge, S., Eastman, B., Glaser, S.M., Dandapani, S., Lee, P., Wong, J.Y.C., Chan, K., Lau, C., Yip, W., Dorff, T.B., Li, Y.R.

“…Treatments for prostate cancer (PCa) can profoundly impact sexual health (SH). Previous studies have found that PCa patients (pts) are concerned about their SH…”
Get full text

Machine Learning to Predict Genomic Risk Score/Classification in Prostate Cancer by Tizpa, E., Tam, A., Maroongroge, S., Amini, A., Glaser, S.M., Dandapani, S.V., Yuh, B., Yoshida, J., Liu, S., Dorff, T.B., Pal, S.K., Yamzon, J., Zhumkhawala, A., Satterthwaite, R., Montez, J., Lee, P., Wong, J.Y.C., Li, Y.R., Ladbury, C.J.

“…A critique of genomic risk classifiers is potential correlation with readily available clinical data. For these classifiers to enhance clinical decision…”
Get full text

Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP) by Dandapani, S.V., Hao, C., Ladbury, C.J., Wong, J.Y.C., Li, Y.R., Liu, J.R., Glaser, S.M., Lee, P., Mandelin, P.M., Pal, S.K., Alcantara, M., Kortylewski, M., Frankel, P., Ruel, C., Chehrazi-Raffle, A., Lyou, Y., Liu, J., Simpson, J., Dorff, T.B., Twardowski, P.

“…While radium 223 dichloride (Ra-223) has been approved for metastatic castrate resistant prostate cancer, there is limited prospective data regarding its use…”
Get full text

7027 Interim results of a phase II trial of oxaliplatin and pemetrexed as 2nd/3rd line therapy in castration resistant prostate cancer (CRPC) by Dorff, T.B, Groshen, S, Tsao-Wei, D.D, Goldkorn, A, Korn, C, Quinn, D.I, Pinski, J

Get full text

Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and External Beam Radiation by Hao, C., Ladbury, C.J., Lyou, Y., Manoukian, S., Ruel, C., Frankel, P., Dorff, T.B., Wong, J.Y.C., Pal, S.K., Twardowski, P., Dandapani, S.V.

Get full text

Real-World Utilization And Outcomes Of Radium-223 In The Treatment Of Metastatic Castrate Resistant Prostate Cancer by Li, R., Dandapani, S.V., Amini, A., Pal, S.K., Dorff, T.B., Lyou, Y., Vapiwala, N., Wong, J.Y.C., Glaser, S.M.

Get full text

Alkaline Phosphatase And Prostate-Specific Antigen Dynamics And Survival Outcomes In Patients With Metastatic Prostate Cancer Receiving Radium-223 by Li, R., Dandapani, S.V., Amini, A., Pal, S.K., Dorff, T.B., Lyou, Y., Vapiwala, N., Wong, J.Y.C., Glaser, S.M.

Get full text

Dosimetric Plan Evaluation of Biology Guided Radiotherapy Using [18F]-DCFPyL PSMA Radiotracer in Patients with Prostate Cancer by Liu, B., Chen, Q., Qing, K., Dandapani, S.V., Li, Y.R., Glaser, S.M., Chen, H.K., Da Silva, A., Leung, D., Feghali, K. A. Al, Simpson, J., Liu, J., Dorff, T.B., Liu, A., Williams, T.M., Wong, J.Y.C.

“…The X1 system represents a cutting-edge solution in radiotherapy delivery, with its capability to perform Biology Guided Radiotherapy (BgRT). The system…”
Get full text

Pilot Study of a Novel Ring Gantry-Based PET/CT Linear Accelerator in Patients with Prostate Cancer Receiving [18F]-DCFPyL for PSMA PET Imaging by Wong, J.Y.C., Liu, B., Dandapani, S.V., Li, Y.R., Glaser, S.M., Liu, J., Chen, Q., Qing, K., Chen, H.K., Simpson, J., Da Silva, A., Leung, D., Feghali, K., Dorff, T.B., Liu, A., Williams, T.M.

“…The RefleXion X1® system is a hybrid PET imaging-radiotherapy system that uses real-time positron emissions from a PET tracer to deliver biologically guided…”
Get full text

A Randomized, Phase II Clinical Trial of Time-Restricted Eating vs. Dietary Counseling to Improve Effect of Radiotherapy (TIDIER) by Eustace, N.J., Huang, Z., Abuali, T., Mercier, B., Feng, Q., Li, C., Ladbury, C.J., Correnti, N., Tang, P., Kurniawan, E., Tam, A., Liu, J.R., Chehrazi-Raffle, A., Tripathi, A., Pal, S.K., Yip, W., Lau, C., Maroongroge, S., Liu, Y., Glaser, S.M., Dandapani, S., Chen, Y.J., Wong, J.Y.C., Lee, P., Williams, T.M., Shuck, S., Sun, V., Mancini, M., Frankel, P., Dorff, T.B., Li, Y.R.

“…Ionizing radiation therapy (RT) acts through the generation of reactive oxygen species (ROS) and the consequent formation of lethal double-strand DNA breaks…”
Get full text

Can Bladder Cancer Biomarkers from Patients Undergoing Cystectomy Predict the Need for Adjuvant Radiotherapy? by Ballas, L.K., Aron, M., Xiong, Y., McCarthy, S., Phuong, C., Sali, A., Chen, M., Clark, E., Tsao-Wei, D., Dorff, T.B., Bhanvadia, S., Magliocco, A., Daneshmand, S.

Get full text

Penile cancer: current therapy and future directions by Sonpavde, G., Pagliaro, L.C., Buonerba, C., Dorff, T.B., Lee, R.J., Di Lorenzo, G.

“…Penile cancer (PC) is a rare cancer in western countries, but is more common in parts of the developing world. Due to its rarity and the consequent lack of…”
Get full text

Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer by Dorff, T.B., Crawford, E.D.

“…Extensive clinical development in metastatic castrate-resistant prostate cancer (mCRPC) has led to the introduction of three new agents in little more than a…”
Get full text

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science by Nussbaum, N, George, D J, Abernethy, A P, Dolan, C M, Oestreicher, N, Flanders, S, Dorff, T B

“…Background: Contemporary therapies for metastatic castration-resistant prostate cancer (mCRPC) have shown survival improvements, which do not account for…”
Get full text

Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: ‘plus or minus’ may be a minus by Dorff, T.B., Quinn, D.I.

Get full text